326 related articles for article (PubMed ID: 4830225)
1. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.
Lewis RJ; Trager WF; Chan KK; Breckenridge A; Orme M; Roland M; Schary W
J Clin Invest; 1974 Jun; 53(6):1607-17. PubMed ID: 4830225
[TBL] [Abstract][Full Text] [Related]
2. Warfarin-phenylbutazone interaction in man: a long term multiple dose study.
Schary WL; Lewis RJ; Rowland M
Res Commun Chem Pathol Pharmacol; 1975 Apr; 10(4):663-72. PubMed ID: 1153844
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of warfarin metabolism by diltiazem in humans.
Abernethy DR; Kaminsky LS; Dickinson TH
J Pharmacol Exp Ther; 1991 Apr; 257(1):411-5. PubMed ID: 2020000
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man.
O'Reilly RA; Trager WF; Motley CH; Howald W
J Clin Invest; 1980 Mar; 65(3):746-53. PubMed ID: 7354137
[TBL] [Abstract][Full Text] [Related]
5. Warfarin metabolites: stereochemical aspects of protein binding and displacement by phenylbutazone.
Chan E; McLachlan AJ; Rowland M
Chirality; 1993; 5(8):610-5. PubMed ID: 8305289
[TBL] [Abstract][Full Text] [Related]
6. Comparative interaction of sulfinpyrazone and phenylbutazone with racemic warfarin: alteration in vivo of free fraction of plasma warfarin.
O'Reilly RA; Goulart DA
J Pharmacol Exp Ther; 1981 Dec; 219(3):691-4. PubMed ID: 7299692
[TBL] [Abstract][Full Text] [Related]
7. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.
Banfield C; O'Reilly R; Chan E; Rowland M
Br J Clin Pharmacol; 1983 Dec; 16(6):669-75. PubMed ID: 6661352
[TBL] [Abstract][Full Text] [Related]
8. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man.
O'Reilly RA
Arch Intern Med; 1984 May; 144(5):989-91. PubMed ID: 6324710
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and metronidazole in rats.
Yacobi A; Lai CM; Levy G
J Pharmacol Exp Ther; 1984 Oct; 231(1):72-9. PubMed ID: 6491976
[TBL] [Abstract][Full Text] [Related]
10. Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats.
Chan E; Hegde A; Chen X
J Pharm Pharmacol; 2009 Apr; 61(4):451-8. PubMed ID: 19298691
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
[TBL] [Abstract][Full Text] [Related]
12. Warfarin: stereochemical aspects of its metabolism in vivo in the rat.
Pohl LR; Bales R; Trager WF
Res Commun Chem Pathol Pharmacol; 1976 Oct; 15(2):233-56. PubMed ID: 981784
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of anticoagulant effect of warfarin by phenylbutazone.
Aggeler PM; O'Reilly RA; Leong L; Kowitz PE
N Engl J Med; 1967 Mar; 276(9):496-501. PubMed ID: 6018280
[No Abstract] [Full Text] [Related]
14. Protein-binding high-performance frontal analysis of (R)- and (S)-warfarin on HSA with and without phenylbutazone.
He J; Shibukawa A; Tokunaga S; Nakagawa T
J Pharm Sci; 1997 Jan; 86(1):120-5. PubMed ID: 9002471
[TBL] [Abstract][Full Text] [Related]
15. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ
Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
[TBL] [Abstract][Full Text] [Related]
16. The stereoselective interaction of warfarin and metronidazole in man.
O'Reilly RA
N Engl J Med; 1976 Aug; 295(7):354-7. PubMed ID: 934223
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
He M; Kunze KL; Trager WF
Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
19. Reduction in the plasma clearance rate of warfarin induced by cimetidine.
Bell WR; Anderson KC; Noe DA; Silver BA
Arch Intern Med; 1986 Dec; 146(12):2325-8. PubMed ID: 3778066
[TBL] [Abstract][Full Text] [Related]
20. Sodium warfarin.
O'Reilly RA
Pharmacology; 1972; 8(1):181-90. PubMed ID: 4644647
[No Abstract] [Full Text] [Related]
[Next] [New Search]
